碳酸锂对抗AFB_1诱导大鼠肝癌过程中MDA、4-HNE的表达及意义

Expression of MDA and 4-HNE in AFB_1-Induced Rat Hepatic Putative Preneoplastic Lesions Alleviated by Li_2CO_3 and Their Significance

背景与目的:采用免疫组化法检测碳酸锂(Li2CO3)对抗黄曲霉素B1(AflatoxinB1,AFB1)诱导大鼠肝癌过程中丙二醛(Malondialdehyde,MDA)、4_羟壬烯醛(4_hydroxynonenal,4_HNE)的表达情况,探讨Li2CO3 的抗癌作用及其机制。材料与方法:144只Wistar大鼠随机分为A、B、C、D4组,分别为阴性、阳性对照及Li2CO3 同时给药和Li2CO3 先期给药组。于实验第6、9、10周分批断头处死动物,取动物的肝脏进行肝组织形态学检查及免疫组织化学染色。结果:C、D两组动物健康状况明显改善,肝癌前病变程度明显减轻;MDA、4_HNE在诱癌早期(实验第6周)即有表达,第10周显著增高,并呈B组>C组>D组>A组的趋势。结论:Li2CO3 具有明显地对抗和抑制化学诱导肝癌过程中的脂质过氧化(Lipidperoxidation,LPO)作用;免疫组化法检测MDA、4_HNE可敏感而特异的反映机体氧化损伤程度,有助于肝癌的早期发现及病变进展的动态观察。

BACKGROUND&AIM: In order to observe the anti-carcinoma use of lithium carbonate(Li 2 CO 3 )and it's mechanism,the histopathological change and the expression of malondialdehyde(MDA)and4-hydroxynonenal(4-HNE)protein in Aflatoxin B 1 (AFB 1 )-induced rat hepatic putative preneoplastic lesions alleviated by lithium carbonate(Li 2 CO 3 ). MATERIAL AND METHODS: One hundred and forty-four healthy Wistar rats(155～175g)were divided randomly into four groups:normal control group(group A),positive control group(group B),group treated with Li 2 CO 3 simultaneously(group C),group pre-treated with Li 2 CO 3 (group D).The rats were killed in batches in the6th,9th or10th week of the experiment.Histopathological and immunohistochemical assay of MDA and4-HNE protein was made on hepatic. RESULTS: The condition of rats was significantly improved in Group C and Group D,so do the severity of preneoplasm.Coinciding with the histopathological discoveries,a tendency of”Group B>Group C>Group D>Group A”could be found in observation of MDA and4-HNE protein expressive,which occurred in the early stage(the6th week)and significantly increased in the10th week. CONCLUSION: It suggested that Li 2 CO 3 has obvious against or restrain lipid peroxidation effect on hepatoma induced by chemicals.The immunohistochemistry assay of MDA and4-HNE can be used as a sensitive and specialize method to reflect oxidative damage,and it may help early finding and monitoring of hepatoma.